Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07463846 | A Study to Evaluate ALN-2232 in Participants With Obesity | PHASE1 | RECRUITING | 156 | — | — | Mar 2, 2026 | Mar 2, 2028 | May 14, 2026 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| Part A: ALN-2232 | EXPERIMENTAL | Participants will be administered a single dose of ALN-2232 |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo |
| Part B: ALN-2232 | EXPERIMENTAL | Participants will be administered multiple doses of ALN-2232 |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will be administered multiple doses of placebo |
| Part C: ALN-2232 | EXPERIMENTAL | Participants will be administered multiple doses of ALN-2232 |
| Part C: Placebo | PLACEBO_COMPARATOR | Participants will be administered multiple doses of placebo |
| Part C: Tirzepatide | OTHER | Participants will be administered multiple doses of tirzepatide once weekly |
| Name | Type | Description |
|---|---|---|
| ALN-2232 | DRUG | ALN-2232 will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo will be administered SC |
| Tirzepatide | DRUG | Tirzepatide will be administered SC |
Inclusion Criteria: All Parts: * Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2 * Has a hemoglobin A1c (HbA1c) \<6.5% Exclusion Criteria: All Parts: * Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise partici...